Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izaf163 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Stefan Schreiber und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany. Hauptthemen laut MEDLINE: Ustekinumab, Crohn Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson.
Abstract (Originalsprache)
Background
The POWER study (NCT03782376) evaluated efficacy and safety of a single ustekinumab intravenous (IV) reinduction dose versus placebo under continued ustekinumab subcutaneous (SC) treatment in adult patients with moderately to severely active Crohn’s disease who demonstrated a secondary loss of response to ustekinumab every 8 weeks (q8w) maintenance therapy.
Methods
Patients were randomly assigned 1:1 at Week 0 to ustekinumab IV reinduction (ustekinumab ∼6 mg/kg and SC placebo) or continuous maintenance (IV placebo and SC ustekinumab 90 mg q8w). Clinical and biomarker assessments occurred at Weeks 0, 8, 16, and 24 with optional ileocolonoscopy at Weeks 0 and16. The primary endpoint was clinical response (≥100-point decrease from baseline Crohn’s Disease Activity Index [CDAI] score or CDAI <150) at Week 16. Safety events were analyzed through Week 36 and serum samples were collected for pharmacokinetic analyses and anti-ustekinumab antibody detection.
Results
Overall, 215 patients were randomized: 108 to the IV reinduction group and 107 to the SC group. In the IV reinduction group, 49.1% achieved clinical response at Week 16 versus 37.4% in the SC group (adjusted treatment difference 11.5% [95% CI: −1.5%, 24.5%; P = .089]). Proportions of patients with endoscopic remission and improvement, normalization of inflammatory biomarkers, and improvement in IBDQ score were greater in the IV reinduction group vs the SC group. No new safety signals were identified.
Conclusions
Although the primary endpoint of clinical response was not met at Week 16, ustekinumab IV reinduction showed numerical improvements in objective endpoints including inflammatory biomarkers and endoscopic outcomes compared with SC maintenance therapy. Safety and immunogenicity results were consistent with the established profile of ustekinumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.
- Division of Gastroenterology, University of Washington, Seattle, WA, United States.
- Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Gastroenterology Unit, Hospital Universitario Gregorio Marañón, IiSGM, Universidad Complutense, Madrid, Spain.
- Center for Crohn's Disease & Ulcerative Colitis, Atlanta Gastroenterology Associates, Atlanta, GA, United States.
- Internal Medicine III, Gastroenterology, University Hospital of Augsburg, Augsburg, Germany.
ORCID-Profile: Stefan Schreiber, Scott D Lee
Förderung
- Johnson & Johnson
Zitieren
APA
Schreiber, S., Lee, S. D., van der Woude, C. J., Marín-Jiménez, I., Wolf, D. C., Schnoy, E., Salzberg, B., Busse, C., Nazar, M., Ma, T., Borghorst, S., Gasink, C., Baker, T., Godwin, B., Adedokun, O. J., Feagan, B. G., & POWER Study Group (2025). Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf163
Vancouver
Schreiber S, Lee SD, van der Woude CJ, Marín-Jiménez I, Wolf DC, Schnoy E, et al. Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf163
BibTeX
@article{Schreiber2025,
author = {Schreiber, Stefan and Lee, Scott D and van der Woude, C Janneke and Marín-Jiménez, Ignacio and Wolf, Douglas C and Schnoy, Elisabeth and Salzberg, Bruce and Busse, Christopher and Nazar, Maciej and Ma, Tony and Borghorst, Stephan and Gasink, Christopher and Baker, Thomas and Godwin, Bridget and Adedokun, Omoniyi J and Feagan, Brian G and POWER Study Group, POWER Study Group},
title = {Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izaf163}
}
EUVIMED